Adjuvant Palbociclib Offers No Benefit to Patients With Early Breast Cancer When Added to Endocrine Therapy
he addition of palbociclib to a 2-year course of adjuvant endocrine therapy did not meaningfully improve invasive disease-free survival (DFS) over endocrine therapy alone in patients with early-stage breast cancer, according to an interim analysis of a phase 3 trial published in The Lancet Oncology. These findings suggest the combination should not be considered an effective regimen for adjuvant therapy, according to the researchers.